Breast Cancer Research

official impact factor 5.79

Highly Access

Breast cancer prognostic classification in the molecular era: the role of histological grade

Emad A Rakha, Jorge S Reis-Filho, Frederick Baehner, David J Dabbs, Thomas Decker, Vincenzo Eusebi, Stephen B Fox, Shu Ichihara, Jocelyne Jacquemier, Sunil R Lakhani, José Palacios, Andrea L Richardson, Stuart J Schnitt, Fernando C Schmitt, Puay-Hoon Tan, Gary M Tse, Sunil Badve and Ian O Ellis*

Breast Cancer Research 2010, 12:207 doi:10.1186/bcr2607

Accesses  

  • Last 30 days: 467 accesses
  • Last 365 days: 4227 accesses
  • All time: 7226 accesses

Cited by

BioMed Central: 4 citations

Research article   Open Access

Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis

Andrea Malfettone, Concetta Saponaro, Angelo Paradiso, Giovanni Simone, Annita Mangia BMC Cancer 2012, 12:106 (22 March 2012)

Research   Open Access Highly Accessed

Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data

Arvydas Laurinavicius, Aida Laurinaviciene, Valerijus Ostapenko, Darius Dasevicius, Sonata Jarmalaite, Juozas Lazutka Diagnostic Pathology 2012, 7:27 (16 March 2012)

Research article   Open Access Highly Accessed

Rare variants in the ATM gene and risk of breast cancer

David E Goldgar, Sue Healey, James G Dowty, Leonard Da Silva, Xiaoqing Chen, Amanda B Spurdle, Mary Terry, Mary J Daly, Saundra M Buys, Melissa C Southey, Irene Andrulis, Esther M John, Kum Khanna, John L Hopper, Peter J Oefner, Sunil Lakhani, Georgia Chenevix-Trench Breast Cancer Research 2011, 13:R73 (25 July 2011)

Review   Free Highly Accessed

Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction

Pierre-Emmanuel Colombo, Fernanda Milanezi, Britta Weigelt, Jorge S Reis-Filho Breast Cancer Research 2011, 13:212 (27 June 2011)

In this review, the authors examine the clinical relevance of microarray-based profiling of breast cancer and discuss its impact on patient management.